ID: ALA557105

Max Phase: Preclinical

Molecular Formula: C33H32ClN3O2

Molecular Weight: 538.09

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)CCCN1CCC2c3ccccc3N(Cc3cccc(/C=C/c4ccc5ccc(Cl)cc5n4)c3)C2C1

Standard InChI:  InChI=1S/C33H32ClN3O2/c34-26-13-11-25-12-15-27(35-30(25)20-26)14-10-23-5-3-6-24(19-23)21-37-31-8-2-1-7-28(31)29-16-18-36(22-32(29)37)17-4-9-33(38)39/h1-3,5-8,10-15,19-20,29,32H,4,9,16-18,21-22H2,(H,38,39)/b14-10+

Standard InChI Key:  UPIUQXNSJMLQJB-GXDHUFHOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 538.09

Molecular Weight (Monoisotopic): 537.2183

AlogP: 7.10

#Rotatable Bonds: 8

Polar Surface Area: 56.67

Molecular Species: ZWITTERION

HBA: 4

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 4.08

CX Basic pKa: 9.72

CX LogP: 4.42

CX LogD: 4.42

Aromatic Rings: 4

Heavy Atoms: 39

QED Weighted: 0.26

Np Likeness Score: -0.70

References

1. Bonjoch J, Diaba F, Pagès L, Pérez D, Soca L, Miralpeix M, Vilella D, Anton P, Puig C..  (2009)  Synthesis and structure-activity relationships of gamma-carboline derivatives as potent and selective cysLT(1) antagonists.,  19  (15): [PMID:19505824] [10.1016/j.bmcl.2009.05.094]

Source

Source(1):

• Scientific Literature